Academic literature on the topic 'Neutralizing antibodies'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Neutralizing antibodies.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Neutralizing antibodies"
Vinson, Valda. "Protective neutralizing antibodies." Science 369, no. 6506 (August 20, 2020): 930.13–932. http://dx.doi.org/10.1126/science.369.6506.930-m.
Full textDempsey, Laurie A. "Zika-neutralizing antibodies." Nature Immunology 18, no. 6 (June 2017): 603. http://dx.doi.org/10.1038/ni.3762.
Full textBell, Elaine. "Neutralizing antibodies revisited." Nature Reviews Immunology 2, no. 6 (June 2002): 387. http://dx.doi.org/10.1038/nri833.
Full textMuharemagic, D., A. S. Zamay, S. M. Ghobadloo, J. C. Bell, and M. V. Berezovski. "APTAMER-FACILITATED PROTECTION OF ONCOLYTIC VIRUS FROM NEUTRALIZING ANTIBODIES." Siberian Medical Review, no. 5 (2016): 116. http://dx.doi.org/10.20333/25000136-2016-5-116-2.
Full textKadkhoda, Kamran. "COVID ‐19: are neutralizing antibodies neutralizing enough?" Transfusion 60, no. 7 (June 3, 2020): 1602–3. http://dx.doi.org/10.1111/trf.15897.
Full textBjorkman, Pamela. "Neutralizing antibodies against coronaviruses." Microscopy and Microanalysis 27, S1 (July 30, 2021): 1112–13. http://dx.doi.org/10.1017/s1431927621004177.
Full textNoronha, A. "Neutralizing antibodies to interferon." Neurology 68, Issue 24, Supplement 4 (June 11, 2007): S16—S22. http://dx.doi.org/10.1212/01.wnl.0000277705.63813.84.
Full textCorti, Davide, and Antonio Lanzavecchia. "Broadly Neutralizing Antiviral Antibodies." Annual Review of Immunology 31, no. 1 (March 21, 2013): 705–42. http://dx.doi.org/10.1146/annurev-immunol-032712-095916.
Full textGrauer, A., H. Reinel, R. Ziegler, and F. Raue. "Neutralizing Antibodies Against Calcitonin." Hormone and Metabolic Research 25, no. 09 (September 1993): 486–88. http://dx.doi.org/10.1055/s-2007-1002156.
Full textO'Connell, Nicola, and Bronwen Roper. "Testing for neutralizing antibodies." British Journal of Neuroscience Nursing 3, no. 2 (February 2007): 65–67. http://dx.doi.org/10.12968/bjnn.2007.3.2.23140.
Full textDissertations / Theses on the topic "Neutralizing antibodies"
Ovcina, Emira. "An immune response to peptides selected with neutralizing antibodies." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2000. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape4/PQDD_0019/MQ59191.pdf.
Full textBonsall, David George. "The role of neutralizing antibodies in HIV-1 infection." Thesis, Imperial College London, 2011. http://hdl.handle.net/10044/1/6360.
Full textZhang, Jianchao. "HIV-1/SIV neutralizing antibody gene delivery a novel vaccination approach /." Columbus, Ohio : Ohio State University, 2009. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1237924213.
Full textLam, Sin Man. "Neutralizing antibodies and the biological response to interferon-beta therapy." Thesis, University of British Columbia, 2010. http://hdl.handle.net/2429/26977.
Full textBurke, Karen L. "Antigen chimaeras of poliovirus." Thesis, University of Reading, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.328967.
Full textWiley, James A. "Monoclonal anti-idiotypes induce neutralizing antibodies to enterovirus-70 conformational epitopes." Thesis, University of Ottawa (Canada), 1992. http://hdl.handle.net/10393/7649.
Full textDerby, Nina Rafterman. "Designing immunogens to elicit broadly reactive neutralizing antibodies to the HIV envelope /." Thesis, Connect to this title online; UW restricted, 2007. http://hdl.handle.net/1773/9302.
Full textAlpert, Michael. "Antibodies in Vaccine Protection against SIV and HIV-1 Infection." Thesis, Harvard University, 2011. http://dissertations.umi.com/gsas.harvard:10057.
Full textYari, Fayezeh. "Expression of recombinant neutralizing anti-HIV-1 antibodies in bacteria and eukaryotic cells /." Stockholm : Karolisnska institutet, 2007. http://diss.kib.ki.se/2007/978-91-7357-079-4/.
Full textMolinos, Albert Luis Manuel. "Targeting a major HIV-1 vulnerability region: the gp41 membrane proximal external region. Balance between neutralizing and non-neutralizing antibodies and implications for vaccine design." Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/392728.
Full textLa generación de anticuerpos ampliamente neutralizantes contra el VIH-1 es el principal objetivo de una vacuna que sea capaz de controlar la epidemia causada por el virus. La glicoproteína de la envuelta del VIH-1 es el único antígeno viral expuesto en la membrana del virus y la principal diana de respuestas humorales protectoras. Dentro de esta proteína se han identificado regiones funcionales que son reconocidas por anticuerpos ampliamente neutralizantes, lo cual ha permitido establecer puntos de vulnerabilidad del virus hacia los que una vacuna debería dirigirse. En este contexto, la región externa próxima a la membrana (MPER) de gp41 es uno de los sitios de vulnerabilidad del virus más representativos, ya que está altamente conservado, juega un papel crucial en la infectividad del virus y es reconocido por anticuerpos protectores ampliamente neutralizantes. Sin embargo, su localización, contigua a la membrana, hace del MPER un dominio poco accesible, expuesto de forma transitoria, hidrofóbico y altamente influenciado por lípidos de membrana. En consecuencia, su inmunogenicidad presenta una alta complejidad que debe ser explorada en mayor profundidad. En esta tesis, aportamos nuevo conocimiento sobre la inmunogenicidad del MPER a nivel de la infección natural y en modelos animales de inmunización. Hemos evaluado miniproteínas basadas en gp41 que sobreexponen el MPER, para ser utilizadas como 1) nuevas plataformas para la detección de anticuerpos anti-MPER y 2) prototipos de inmunógenos presentados en proteoliposomas de diversa composición. Los resultados han revelado una alta inmunogenicidad del MPER en humanos, que correlaciona con la respuesta global contra la proteína de la envuelta. Esto sugiere que el sistema inmune no tiene una especial restricción para la generación de este tipo de anticuerpos. Sin embargo, los anticuerpos detectados mostraron una funcionalidad heterogénea, en términos de capacidad neutralizante y competición por diferentes epítopos, independientemente de la especificidad por el MPER. Además, los resultados fueron reproducidos en animales inmunizados. En estos últimos, conseguimos generar un alto título de anticuerpos específicos, potenciados por la incorporación en los proteoliposomas de mezclas lipídicas complejas que mimetizaban las de la partícula viral. Sorprendentemente, se generó una respuesta inmunodominante no neutralizante que solapaba con un epítopo reconocido por el anticuerpo neutralizante 2F5. En resumen, la repuesta humoral natural contra el MPER en pacientes infectados por el VIH-1 y la generada en modelos animales mediante inmunización comparten ciertas características como son la especificidad y la escasa capacidad neutralizante. Estos resultados sugieren que el balance entre la respuesta neutralizante y no neutralizante podría tener una importante relevancia en la respuesta global contra el MPER. De este modo, es necesario un mayor refinamiento de inmunógenos que sean capaces de sortear respuestas no neutralizantes. Este rediseño se verá altamente beneficiado del conocimiento generado a partir de nuevos anticuerpos monoclonales contra el MPER que reflejen la heterogeneidad funcional observada en nuestros estudios.
The elicitation of broadly neutralizing antibodies (bNAbs) against HIV-1 constitutes the major goal of an effective vaccine able to control the epidemic caused by this virus. The HIV-1 envelope glycoprotein is the only viral antigen exposed on the surface of the virus and the main target of protective humoral responses. The identification within this protein of functional regions recognized by bNAbs has delineated an HIV-1 vulnerability map that has guided efforts for rational immunogen design. In this regard, the gp41 Membrane Proximal External Region (MPER) is a major HIV-1 vulnerability site because is highly conserved, plays a major role in viral infectivity and is targeted by protective bNAbs. However, its localization, next to the viral membrane, results in a hardly accessible, transiently exposed and hydrophobic domain, strongly influenced by membrane lipids. Therefore, the immunogenicity of the MPER offers a high level of complexity that needs to be further explored. In this thesis we provide new knowledge on the MPER immunogenicity in both natural HIV-1 infection and immunization in animal models. We generated gp41-based miniproteins which properly exposed the MPER region that have been used 1) as novel platforms for MPER antibody detection and 2) as immunogen candidates presented in different proteoliposome compositions. In humans, the results revealed a strong immunogenicity of the MPER that correlated with a global response against the envelope glycoprotein suggesting no special constraints for the immune system to target this region. However, the antibodies elicited showed heterogeneous functionality in terms of neutralizing capacity and epitope competition, regardless MPER specificity. Interestingly, these results were reproduced by immunization in animal models. High antibody titers were achieved that were specially enhanced by the addition of lipid mixtures mimicking the viral membrane. Interestingly, a non-neutralizing immunodominant response against an epitope that overlapped the 2F5 neutralizing antibody binding motif was identified. Overall, the anti-MPER response in both humans and animal model settings was not correlated with the neutralizing capacity and antibodies detected or induced by immunization were preferentially non-neutralizing. Our results suggest that the balance between neutralizing and non neutralizing responses may represent an important issue in the global response against MPER. Therefore, further redesign of immunogens able to skip non-neutralizing determinants will benefit from the knowledge derived from new anti-MPER antibodies that reflect the functional heterogeneous profile observed in our studies.
Books on the topic "Neutralizing antibodies"
Tovey, Michael G. Detection and quantification of antibodies to biopharmaceuticals: Practical and applied considerations. Hoboken, N.J: Wiley, 2011.
Find full textO'Rourke, Katherine. Neutralizing and cross neutralizing antibodies in horses with equine infectious anemia virus. 1987.
Find full textTovey, Michael G. Detection and Quantification of Antibodies to Biopharmaceuticals. Wiley & Sons, Incorporated, John, 2011.
Find full textChiodi, Francesca, and Gabriella Scarlatti, eds. HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies. Frontiers Media SA, 2018. http://dx.doi.org/10.3389/978-2-88945-461-7.
Full textSchommers, Philipp, Harry Gristick, Marit J. Van Gils, and Kshitij Wagh, eds. Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88974-305-6.
Full textTovey, Michael G. Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Wiley & Sons, Limited, John, 2011.
Find full textTovey, Michael G. Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Wiley & Sons, Incorporated, John, 2011.
Find full textTovey, Michael G. Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Wiley & Sons, Incorporated, John, 2011.
Find full textTovey, Michael G. Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Wiley & Sons, Incorporated, John, 2011.
Find full textCox, Josephine H., Stuart Z. Shapiro, Liza Dawson, Cynthia Geppert, Andrew M. Siegel, and M. Patricia D’Souza. Vaccines for The Prevention and Treatment of HIV Infection. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0032.
Full textBook chapters on the topic "Neutralizing antibodies"
Robert-Guroff, Marjorie. "Neutralizing Antibodies." In Techniques in HIV Research, 179–85. London: Palgrave Macmillan UK, 1990. http://dx.doi.org/10.1007/978-1-349-11888-5_9.
Full textKunert, Renate. "The Neutralizing Anti-HIV Antibody 2G12." In Anticarbohydrate Antibodies, 147–60. Vienna: Springer Vienna, 2011. http://dx.doi.org/10.1007/978-3-7091-0870-3_6.
Full textSuitters, Amanda, and Roly Foulkes. "Cytokine-neutralizing therapeutic antibodies." In Novel Cytokine Inhibitors, 123–43. Basel: Birkhäuser Basel, 2000. http://dx.doi.org/10.1007/978-3-0348-8450-1_6.
Full textMoulard, Maxime, Mei-Yun Zhang, and Dimiter S. Dimitrov. "Novel Hiv Neutralizing Antibodies Selected from Phage Display Libraries." In Antibodies, 105–17. Boston, MA: Springer US, 2004. http://dx.doi.org/10.1007/978-1-4419-8877-5_5.
Full textAbraham, Edward. "Neutralizing antibodies and receptor constructs." In Cytokines in Severe Sepsis and Septic Shock, 285–93. Basel: Birkhäuser Basel, 1999. http://dx.doi.org/10.1007/978-3-0348-8755-7_16.
Full textLansky, David, and Carrie Wager. "Dilutional Linearity for Neutralizing Antibody Assays." In Detection and Quantification of Antibodies to Biopharmaceuticals, 309–17. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118075685.ch17.
Full textRuprecht, Ruth M. "Passive Immunization with Human Neutralizing Monoclonal Antibodies Against HIV-1 in Macaque Models: Experimental Approaches." In Therapeutic Antibodies, 559–66. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-554-1_31.
Full textZhang, Mei-Yun, and Dimiter S. Dimitrov. "Competitive Antigen Panning for Selection of HIV-1 Neutralizing Human Monoclonal Antibodies Specific for gp41." In Therapeutic Antibodies, 175–86. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-554-1_9.
Full textGrossberg, Sidney E., and Yoshimi Kawade. "The Expression of Potency of Neutralizing Antibodies for Interferons and other Cytokines." In Antibodies in Cytokines, 93–98. Dordrecht: Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-011-5664-6_10.
Full textWu, Xueling. "HIV Broadly Neutralizing Antibodies: VRC01 and Beyond." In HIV Vaccines and Cure, 53–72. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-0484-2_3.
Full textConference papers on the topic "Neutralizing antibodies"
Morton, Scott P., and Joshua L. Phillips. "pH Dependent Binding Energies of Broadly Neutralizing Antibodies." In 2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2021. http://dx.doi.org/10.1109/bibm52615.2021.9669511.
Full textJohnsson, H., A. Silveira, L. Adamson, S. Schulman, and B. Hessel. "INDUCED ANTIBODIES TO VON WILLEBRAND FACTOR (VWF)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644112.
Full textSolodkov, P. P., T. N. Belovezhets, A. N. Chikaev, K. O. Baranov, S. V. Kulemzin, A. A. Gorchakov, S. V. Guselnikov, et al. "SINGLE DOMAIN LLAMA ANTIBODIES BROADLY NEUTRALIZING SARS-COV-2 VARIANTS." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-127.
Full textSun, Jing, Guang Lan Zhang, Lars Rønn Olsen, Ellis L. Reinherz, and Vladimir Brusic. "Landscape of neutralizing assessment of monoclonal antibodies against dengue virus." In BCB'13: ACM-BCB2013. New York, NY, USA: ACM, 2013. http://dx.doi.org/10.1145/2506583.2512359.
Full textDias, Brenda, Andrea Silva, Ariane Souza, Luma Moura, Nathália Alves, Vanessa Rocha, Ana Argondizzo, Sheila Lima, Helena Toma, and Adriana Azevedo. "Neutralizing antibodies and igg avidity against SARS-CoV-2 variants." In International Symposium on Immunobiologicals. Instituto de Tecnologia em Imunobiológicos, 2023. http://dx.doi.org/10.35259/isi.2023_58035.
Full textKent, Michael, Maxwell Stefan, Brooke Harmon, Daniel Gelperin, Valerie Duva, Alyssa Wynne, and Valeria Busygina. "Rapidly Adapting Neutralizing Antibodies to Related Virus Types and Subtypes." In Proposed for presentation at the Biophysical Society Annual Meeting 2021 held February 22-26, 2021. US DOE, 2021. http://dx.doi.org/10.2172/1842569.
Full textGavrilova, N. V., V. V. Vysochinskaya, E. A. Elpaeva, O. A. Dobrovolskaya, M. A. Plotnikova, A. A. Lozhkov, E. L. Zimmerman, A. A. Shaldzhyan, and Y. A. Zabrodskaya. "ANTIVIRAL ACTIVITY OF MRNAS ENCODING ANTIBODIES, TARGETING INFLUENZA A HEMAGGLUTININ AND INFLUENZA B NUCLEOPROTEIN IN VITRO." In OpenBio-2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-239.
Full textRak, A. Ya, Ya A. Zabrodskaya, N. P. Gorbunov, D. S. Polyakov, D. A. Mezhenskaya, L. G. Rudenko, and I. N. Isakova-Sivak. "DEVELOPMENT OF A UNIVERSAL DIAGNOSTIC TEST SYSTEM FOR DETERMINING THE TITER OF ANTIBODIES AGAINST SARS-COV-2 BY MICRONEUTRALIZATION." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-226.
Full textAllaf, L. Al, A. Chechushkov, T. Ushakova, V. Morozova, and N. Tikunova. "INFLUENCE OF HUMORAL IMMUNE RESPONSE TO BACTERIOPHAGE ON PHAGE-THERAPY AND ANTI-BACTERIAL IMMUNITY." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-223.
Full textZimonina, A. A., E. Yu Prudnikova, and A. R. Imatdinov. "RECOMBINANT MONOCLONAL ANTIBODIES WITH VIRUS NEUTRALIZING ACTIVITY AGAINST SARS-COV-2 DELTA AND OMICRON VARIANTS." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-81.
Full textReports on the topic "Neutralizing antibodies"
Glassy, Mark C. Neutralizing Monoclonal Antibodies against Biological Toxins. Phase 1. Fort Belvoir, VA: Defense Technical Information Center, August 1993. http://dx.doi.org/10.21236/adb176298.
Full textIvanova, Sonya, Raliza Skrobanska, Vera Kolyovska, and Ivan Milanov. Do Binding Antibodies Predict Neutralizing Antibody Development in Multiple Sclerosis Patients? "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, August 2018. http://dx.doi.org/10.7546/crabs.2018.08.17.
Full textIvanova, Sonya, Raliza Skrobanska, Vera Kolyovska, Ivan Milanov, Valentina Dimitrova, and Veneta Bojinova. Neutralizing Antibodies against Interferon‑beta in Bulgarian Adolescent Multiple Sclerosis Patients. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, September 2018. http://dx.doi.org/10.7546/crabs.2018.09.15.
Full textMogler, Mark, and D. L. Hank Harris. Passive Immunization of Piglets Using Equine Plasma Containing PRRS Virus-Neutralizing Antibodies. Ames (Iowa): Iowa State University, January 2008. http://dx.doi.org/10.31274/ans_air-180814-171.
Full textKaniewski, Laura, Jason Hocker, Mark Mogler, Matthew M. Erdman, Eric Nelson, and D. L. Hank Harris. Passive Immunization of Piglets with Hyperimmune Plasma Containing Virus Neutralizing Antibodies to Porcine Reproductive and Respiratory Syndrome Virus. Ames (Iowa): Iowa State University, January 2009. http://dx.doi.org/10.31274/ans_air-180814-65.
Full textMackey, Katherine, Irina Arkhipova-Jenkins, Charlotte Armstrong, Emily Gean, Johanna Anderson, Robin A. Paynter, and Mark Helfand. Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Rapid Living Review. Agency for Healthcare Research and Quality (AHRQ), March 2021. http://dx.doi.org/10.23970/ahrqepccovidimmunity.
Full textJuni, Peter, Ashleigh R. Tuite, Issac I. Bogoch, Adalsteinn D. Brown, Yoojin Choi, Bruno R. da Costa, Gerald A. Evans, et al. Rollout Strategy for the Pfizer-BioNTech COVID-19 Vaccine in Ontario. Ontario COVID-19 Science Advisory Table, January 2021. http://dx.doi.org/10.47326/ocsat.2021.02.06.1.0.
Full text